These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 25696858)

  • 1. Iron age: novel targets for iron overload.
    Casu C; Rivella S
    Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):216-21. PubMed ID: 25696858
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modulation of hepcidin as therapy for primary and secondary iron overload disorders: preclinical models and approaches.
    Schmidt PJ; Fleming MD
    Hematol Oncol Clin North Am; 2014 Apr; 28(2):387-401. PubMed ID: 24589273
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RNAi-mediated reduction of hepatic Tmprss6 diminishes anemia and secondary iron overload in a splenectomized mouse model of β-thalassemia intermedia.
    Schmidt PJ; Liu K; Visner G; Fitzgerald K; Fishman S; Racie T; Hettinger JL; Butler JS; Fleming MD
    Am J Hematol; 2018 Jun; 93(6):745-750. PubMed ID: 29498084
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Iron and hepcidin: a story of recycling and balance.
    Camaschella C
    Hematology Am Soc Hematol Educ Program; 2013; 2013():1-8. PubMed ID: 24319154
    [TBL] [Abstract][Full Text] [Related]  

  • 5. mRNA expression of iron regulatory genes in beta-thalassemia intermedia and beta-thalassemia major mouse models.
    Weizer-Stern O; Adamsky K; Amariglio N; Rachmilewitz E; Breda L; Rivella S; Rechavi G
    Am J Hematol; 2006 Jul; 81(7):479-83. PubMed ID: 16755567
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New strategies to target iron metabolism for the treatment of beta thalassemia.
    Oikonomidou PR; Casu C; Rivella S
    Ann N Y Acad Sci; 2016 Mar; 1368(1):162-8. PubMed ID: 26919168
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepcidin as a therapeutic tool to limit iron overload and improve anemia in β-thalassemic mice.
    Gardenghi S; Ramos P; Marongiu MF; Melchiori L; Breda L; Guy E; Muirhead K; Rao N; Roy CN; Andrews NC; Nemeth E; Follenzi A; An X; Mohandas N; Ginzburg Y; Rachmilewitz EA; Giardina PJ; Grady RW; Rivella S
    J Clin Invest; 2010 Dec; 120(12):4466-77. PubMed ID: 21099112
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ineffective erythropoiesis and regulation of iron status in iron loading anaemias.
    Camaschella C; Nai A
    Br J Haematol; 2016 Feb; 172(4):512-23. PubMed ID: 26491866
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New thiazolidinones reduce iron overload in mouse models of hereditary hemochromatosis and β-thalassemia.
    Liu J; Liu W; Liu Y; Miao Y; Guo Y; Song H; Wang F; Zhou H; Ganz T; Yan B; Liu S
    Haematologica; 2019 Sep; 104(9):1768-1781. PubMed ID: 30792208
    [TBL] [Abstract][Full Text] [Related]  

  • 10. β-thalassemia: a model for elucidating the dynamic regulation of ineffective erythropoiesis and iron metabolism.
    Ginzburg Y; Rivella S
    Blood; 2011 Oct; 118(16):4321-30. PubMed ID: 21768301
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anemia, ineffective erythropoiesis, and hepcidin: interacting factors in abnormal iron metabolism leading to iron overload in β-thalassemia.
    Gardenghi S; Grady RW; Rivella S
    Hematol Oncol Clin North Am; 2010 Dec; 24(6):1089-107. PubMed ID: 21075282
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Minihepcidins improve ineffective erythropoiesis and splenomegaly in a new mouse model of adult β-thalassemia major.
    Casu C; Chessa R; Liu A; Gupta R; Drakesmith H; Fleming R; Ginzburg YZ; MacDonald B; Rivella S
    Haematologica; 2020 Jul; 105(7):1835-1844. PubMed ID: 31582543
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Deletion of TMPRSS6 attenuates the phenotype in a mouse model of β-thalassemia.
    Nai A; Pagani A; Mandelli G; Lidonnici MR; Silvestri L; Ferrari G; Camaschella C
    Blood; 2012 May; 119(21):5021-9. PubMed ID: 22490684
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ineffective Erythropoiesis: Anemia and Iron Overload.
    Gupta R; Musallam KM; Taher AT; Rivella S
    Hematol Oncol Clin North Am; 2018 Apr; 32(2):213-221. PubMed ID: 29458727
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepcidin.
    Ganz T
    Rinsho Ketsueki; 2016; 57(10):1913-1917. PubMed ID: 27725588
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Iron metabolism and ineffective erythropoiesis in beta-thalassemia mouse models.
    Ramos P; Melchiori L; Gardenghi S; Van-Roijen N; Grady RW; Ginzburg Y; Rivella S
    Ann N Y Acad Sci; 2010 Aug; 1202():24-30. PubMed ID: 20712768
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepcidin and Anemia: A Tight Relationship.
    Pagani A; Nai A; Silvestri L; Camaschella C
    Front Physiol; 2019; 10():1294. PubMed ID: 31649559
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepcidin levels and iron status in beta-thalassemia major patients with hepatitis C virus infection.
    Hendy OM; Allam M; Allam A; Attia MH; El Taher S; Eldin MM; Ali A
    Egypt J Immunol; 2010; 17(2):33-44. PubMed ID: 23082485
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correcting β-thalassemia by combined therapies that restrict iron and modulate erythropoietin activity.
    Casu C; Pettinato M; Liu A; Aghajan M; Lo Presti V; Lidonnici MR; Munoz KA; O'Hara E; Olivari V; Di Modica SM; Booten S; Guo S; Neil G; Miari R; Shapir N; Zafir-Lavie I; Domev H; Ferrari G; Sitara D; Nai A; Rivella S
    Blood; 2020 Oct; 136(17):1968-1979. PubMed ID: 32556142
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peroxiredoxin-2: A Novel Regulator of Iron Homeostasis in Ineffective Erythropoiesis.
    Matte A; De Falco L; Federti E; Cozzi A; Iolascon A; Levi S; Mohandas N; Zamo A; Bruno M; Lebouef C; Janin A; Siciliano A; Ganz T; Federico G; Carlomagno F; Mueller S; Silva I; Carbone C; Melisi D; Kim DW; Choi SY; De Franceschi L
    Antioxid Redox Signal; 2018 Jan; 28(1):1-14. PubMed ID: 28793778
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.